NCT Number: NCT00887861
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Novartis Investigator Site, Berlin, Germany
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- A diagnosis of partial seizures (with or without secondary generalization) and undergoing an evaluation for epilepsy surgery, based on the classification of the International League Against Epilepsy (ILAE), as modified in 1981.
- Absence of evolving space-occupying lesions or progressive neurological diseases.
- Have normal vital signs (systolic and diastolic blood pressure and pulse rate)
- All female subjects must have negative pregnancy test results
- Subjects must weigh at least 50 kg to participate in this study and must have a body mass index (BMI) within the range of 18 to 35.
Exclusion criteria
- A history of frequent and/or severe status epilepticus (i.e. requiring intensive care unit treatment).
- Current treatment with phenobarbital, primidone or zonisamide (these drugs would have to be completely washed out before study start)
- Having discontinued chronic benzodiazepine and barbiturate therapy within 30 days prior to the study start
- Having electrodes implanted in the brain.
- Having evidence on physical examination, or a history of any medically significant thyroid, cardiac, respiratory, hepatic, gastrointestinal, renal, hematologic, oncologic, psychiatric or progressive neurological disorder, requiring current medical intervention/therapy likely to have a significant impact on the outcome of this study.
- With any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, e.g. GI surgery and/or pancreatic or liver disease
- Having a significant illness other than epilepsy within two (2) weeks prior to initial dosing.
- Having recent (within the last three (3) years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).
Other protocol-defined inclusion/exclusion criteria may apply
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Measure: An efficacy of investigation drug versus Placebo in reducing the seizure rate when administered orally for up to 7days as monotherapy in patients with refractory partial seizures who are undergoing an inpatient evaluation for epilepsy
Time frame: 7 days
Secondary outcomes
-
Measure:An efficacy of investing. drug vs. Pcb in reducing the seizure rate when administered orally for up to 9days (during titration monotherapy)in pts. with refractory partial seizures who are undergoing an inpatient evaluation for epilepsy surgery.
Time frame: 9 days
-
Measure: To evaluate the safety and tolerability of investigational drug repeated dose over 9 days in patients with refractory partial seizures
Time frame: 9 days
-
Measure: To determine the plasma levels of investigational drug in patients with refractory partial seizures.
Time frame: 9 days
Sponsors and collaborators
Lead sponsor
Novartis
Industry
Registry information
Official study title
A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Parallel-group Study of BGG492 as Monotherapy in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
Important dates
- Study start
- 2009
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Apr 24, 2009
- Registry last updated
- Mar 21, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
NCT06714448
Brain Diseases, Central Nervous System Diseases
Chilly-Mazarin, France
View Trial DetailsPivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsEvaluating the Role of Inflammation in Neonatal Epileptogenesis
NCT04259125
Brain Diseases, Central Nervous System Diseases
Oakland, California, United States
View Trial DetailsDevelopment of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram
NCT03369522
Brain Diseases, Central Nervous System Diseases
Béthune, France
View Trial Details